iPSC Development Service
iPSCs are cells that have been artificially reprogrammed from a somatic state to a pluripotent state. In the field of rare diseases, iPSCs have been used for directed differentiation into various types of cells, and have been used in preclinical projects. Our company offers comprehensive and professional services to construct normal and sufferer-specific iPSC models in accordance with your needs.
iPSCs Reprogramming
At present, a series of techniques for reprogramming somatic cells into iPSCs have been established. Transgenic and chemical reprogramming are two dominating strategies for iPSCs, for which some researches have provided optimization protocols to improve their reprogramming efficiency.
Transgenic Reprogramming
Sufferer-derived skin fibroblasts or cells from tissue of disease can be reprogrammed to pluripotent state after ectopic expression of Oct3/4, Sox2, c-Myc, and Klf4. Alternatively, some other transcription factors could be used to replace the above four pluripotency factors, depending on the possible differences in reprogramming efficiency in different cells. To achieve stable expression, each of these pluripotency factors must be inserted into the genome of the cell. Therefore, a variety of transgenic approaches have been applied to induce pluripotent stem cells.
- CRISPRa system
- Retroviral vector
- Lentiviral vector
- Adenoviral vector
- Sendai viral vector
- Episomal plasmid vector
- Direct delivery of synthetic mRNAs
Chemical Reprogramming
Chemical/small molecule-based reprogramming strategies have shown the advantage of being more efficient. The application of histone deacetylase inhibitor, MAPK/ERK kinase inhibitor or small-molecule cocktail, in combination with transgenic strategies, significantly improves the reprogramming efficiency and shortens the induction time. These strategies have made great progress in the field of rare diseases, including the construction of iPSCs for diseases associated with nervous system, blood, and immune system,etc., for the subsequent basic and preclinical research.
- Inhibition factors
- Small molecule cocktail
iPSCs Differentiation
Since iPSCs are pluripotent, these cells can theoretically differentiate into any type of cells involved in rare diseases. For rare diseases, the establishment of sufferer-derived iPSCs not only solves the problem of cell scarcity, but also allows directional differentiation into any cell type in order to realistically reflect pathological development and drug response. Typically, when a rare disease is caused by mutations in multiple genes, iPSCs is an advantageous operational model platform.
For iPSCs differentiation, introducing specific transcription factors and cultivating in appropriate media are approaches to promote differentiation into the expected cell type. In the study of rare diseases, sufferer-derived iPSCs have been induced into different cells, such as dopaminergic neurons, cholinergic neurons, and retinal pigment epithelial cells. Then the cells carrying the same genetic background as the sufferer are used for downstream customized therapy.
Fig.1 iPSCs from sufferers with rare and undiagnosed complicated diseases can be directed to differentiate into different cell types or organoids in vitro (Wang et al. 2022) Our Services
The reprogramming of iPSCs and directional differentiation are advanced applications in the study of rare diseases, allowing you to develop the sufferer-specific disease models and conduct personalized drug testing. Our company provides you with experienced team and necessary resources for efficient reprogramming of iPSCs as well as customized differentiation to support your research in rare diseases. Our services include but are not limited to:
iPSCs Reprogramming Service
- Transgenic Reprogramming
- Chemical Reprogramming
iPSCs Culture Service
- iPSC Culture Optimization
- iPSC Expansion
Transfection Service
- Lipid-mediated Transfection
- Viral Transfection
- Electroporation
Genome Editing Service
- Gene Mutation in iPSCs
- Gene Replace in iPSCs
- Gene Overexpression in iPSCs
iPSCs Differentiation Service
- To Neural Cells
- To Cardiomyocytes
- To Muscle Cells
- To Hematopoietic Cells
iPSCs Characterization Analysis
- Genetic Stability Verification
- Self-renewal and Markers Validation
- Differentiation Potential Assessment
- Differentiated Cell Identity Verification
Workflow of iPSCs reprogramming and differentiation:
- Cel Reprogramming
- Transfection
- Genome Editing
- Differentiation
- Analysis
Our Advantages
Efficient and time-saving differentiation strategies
Rigorous identification rules and standards
Ensuring repeatability of results
Comprehensive and efficient pluripotency induction system
With complete experimental equipment and mature induction system of stem cells, our company offers you with various induction strategies to assist your construction of the iPSCs for the rare diseases of your interest. We also provide you the optimization services for the induction protocol of special somatic cells. If you are interested in our iPSCs development services, please contact us for more information.
Reference
- Wang G, et al. Rare and undiagnosed diseases: From disease-causing gene identification to mechanism elucidation. Fundamental Research, 2022, 2 (6):918-928
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.